Author name: R A

To order this detailed 370+ page report, please visit this link Key Inclusions A detailed analysis of ongoing, biomarker-based clinical trials initiated by big pharmaceutical companies, featuring details on immuno-oncology biomarkers and disease indications being investigated, based on trial registration year, phase of development, recruitment status, therapy design and type of cancer therapy. An analysis […]

Over time, pharmaceutical players have demonstrated significant interest in this domain and have launched clinical research initiatives to investigate the relevance and applications of these novel biomarkers. Several companies have already developed / are developing analytical tests for novel cancer biomarkers (TMB, MSI / MMR and TILs), intended to assist physicians in making personalized treatment

Roots Analysis has done a detailed study on Cancer Biomarkers Market: Focus on TMB, MSI / MMR and TILs Testing, 2019-2030, covering key aspects of the industry and identifying key future growth opportunities.   To order this 370+ page report, which features 190+ figures and 180+ tables, please visit this link   Key Market Insights

Advances in biotechnology have enabled the identification of several novel biomarkers, which are presently being used for a variety of purposes, including diagnosis, drug development, clinical research and to facilitate therapy-related decisions Roots Analysis is pleased to announce the publication of its recent study, titled, “Cancer Biomarkers Market: Focus on TMB, MSI / MMR and

To order this detailed 480+ page report, please visit this link   Key Inclusions A detailed assessment of the current market landscape, including information on drug developer(s), phase of development (marketed, clinical and preclinical / discovery stage) of lead candidates, target immune checkpoints, their respective mechanisms of action (inhibitory or stimulatory),  type of therapeutic modality

Despite the fact that biopharmaceuticals offer significant profit margins, innovator companies are plagued by high costs of development, complex production protocols and special procedures and equipment for fill / finish operations. Consequently, a number of drug manufacturers have demonstrated a preference for outsourcing fill / finish operations of such products.   To order this 480+

Roots Analysis has done a detailed study on Biologics Fill / Finish Services Market, 2019-2030, covering key aspects of the industry’s evolution and identifying potential future growth opportunities. To order this 480+ page report, which features 237 figures and 267 tables, please visit this link Key Market Insights Over 115 companies located in various regions

A steadily growing demand for biologic fill / finish services has generated a range of new opportunities for contract service providers; stakeholders have invested heavily to ensure product integrity and safety   Roots Analysis is pleased to announce the publication of its recent study, titled, “Biologics Fill / Finish Services Market, 2019-2030.”   The report

To order this detailed 400+ page report, please visit this link   Key Inclusions A detailed review of the overall landscape of medical device CROs, along with information on year of establishment, company size, location of headquarters, type of service offered by [A] clinical service providers (biostatistics, consulting, clinical operations, post marketing surveillance / studies,

Given the complex R&D protocols and the increasing demand for clinical evidence of therapeutic benefit, there seems to be a lucrative opportunity for contract research providers engaged in the medical devices’ domain. In fact, since 2000, 150 new CROs have been established that offer a variety of cost-efficient services and solutions to medical device developers.